Form 4 for JSPR Jasper Therapeutics, Inc.
Accepted 2024-03-12 00:00:00 ET · period of report 2024-03-12 · accession 0001213900-24-021961 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-12 | 2024-03-12 | JSPR | Mahal Jeetinder Singh | COO | S - Sale+OE | $26.44 | -900 | 25.0K | -3% | -$23.8K |
| D | 2024-03-12 | 2024-03-12 | JSPR | Mahal Jeetinder Singh | COO | M - OptEx | $7.10 | +900 | 25.9K | +4% | +$6,390 |
| D | 2024-03-12 | 2024-03-12 | JSPR | Mahal Jeetinder Singh | COO | M - OptEx | $0.00 | +900 | 16.5K | +6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Stock | 2024-03-12 | S | D | 900 | $26.44 | 25,009 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.79, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. |
| 2 | Common | Voting Common Stock | 2024-03-12 | M | A | 900 | $7.10 | 25,909 | D | — | — | (F2) Effective on January 4, 2024, the Issuer conducted a reverse stock split of its voting common stock at a ratio of 1-for-10 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split. |
| 3 | Derivative | Stock Option (right to buy) | 2024-03-12 | M | A | 900 | $0.00 | 16,472 | D | $7.10 · — to 2030-05-31 | 900 Voting Common Stock | (F4) The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split. (F5) 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter. |